Skip to main content
main-content

06.03.2019 | Original Research Article

Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children

Zeitschrift:
Clinical Pharmacokinetics
Autoren:
Elizabeth J. Thompson, Huali Wu, Anil Maharaj, Andrea N. Edginton, Stephen J. Balevic, Marjan Cobbaert, Anthony P. Cunningham, Christoph P. Hornik, Michael Cohen-Wolkowiez
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s40262-018-00733-1) contains supplementary material, which is available to authorized users.

Abstract

Objective

The aims of this study were to (1) determine whether opportunistically collected data can be used to develop physiologically based pharmacokinetic (PBPK) models in pediatric patients; and (2) characterize age-related maturational changes in drug disposition for the renally eliminated and hepatically metabolized antibiotic trimethoprim (TMP)–sulfamethoxazole (SMX).

Methods

We developed separate population PBPK models for TMP and SMX in children after oral administration of the combined TMP–SMX product and used sparse and opportunistically collected plasma concentration samples to validate our pediatric model. We evaluated predictability of the pediatric PBPK model based on the number of observed pediatric data out of the 90% prediction interval. We performed dosing simulations to target organ and tissue (skin) concentrations greater than the methicillin-resistant Staphylococcus aureus (MRSA) minimum inhibitory concentration (TMP 2 mg/L; SMX 9.5 mg/L) for at least 50% of the dosing interval.

Results

We found 67–87% and 71–91% of the observed data for TMP and SMX, respectively, were captured within the 90% prediction interval across five age groups, suggesting adequate fit of our model. Our model-rederived optimal dosing of TMP at the target tissue was in the range of recommended dosing for TMP–SMX in children in all age groups by current guidelines for the treatment of MRSA.

Conclusion

We successfully developed a pediatric PBPK model of the combination antibiotic TMP–SMX using sparse and opportunistic pediatric pharmacokinetic samples. This novel and efficient approach has the potential to expand the use of PBPK modeling in pediatric drug development.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
Supplementary material 1 (DOCX 994 kb)
40262_2018_733_MOESM1_ESM.docx
Literatur
Über diesen Artikel